Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology

Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of c...

Descripción completa

Detalles Bibliográficos
Autores principales: Hercun, Julian, Vincent, Catherine, Bilodeau, Marc, Lapierre, Pascal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280269/
https://www.ncbi.nlm.nih.gov/pubmed/35844534
http://dx.doi.org/10.3389/fimmu.2022.907591

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280269/
https://www.ncbi.nlm.nih.gov/pubmed/35844534
http://dx.doi.org/10.3389/fimmu.2022.907591

Ejemplares similares